DarioHealth (NASDAQ: DRIO) chief medical officer Omar Manejwala, MD, will be participating in the upcoming virtual DTx Europe conference. This year’s conference theme is Defining the Success of Digital Therapeutics; Manejwala’s presentation is titled “Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System.” His presentation is scheduled for July 14, 2021, at 5:55 a.m. ET. DTx Europe brings together leaders of digital therapeutic companies, pharmaceutical companies, government and private health care entities to share their learnings and promote the success of innovative technology. Manejwala’s presentation will provide perspective on the impacts of the pandemic going forward and guidance on leveraging digital therapeutics for maximum impact in a greatly changed healthcare ecosystem. “The increased adoption of digital therapeutics during the pandemic offered a promising view into the future of digital therapeutics as people successfully used these solutions to manage their health outside of the doctor’s office,” said DarioHealth chief medical officer Omar Manejwala in the press release. “As we resume more normal activities, the role of digital therapeutics should evolve so we can more effectively address outcomes and costs for a wide variety of conditions.”
To register for the event, visit https://ibn.fm/3Vwz9
To view the full press release, visit https://ibn.fm/SIKAW
About DarioHealth Corp.
DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software,;and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology, utilizing a performance-based approach to improve users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
